Visit

30 Mar

2021

Latest Humira dispute highlights biosimilar trade secrets dangers

AbbVie’s clash with an adalimumab biosimilar producer is the latest in a string of lawsuits showing why biologics originators and imitators need strategies to protect proprietary information

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth

TAGS

Litigation, Trade Secrets, Life Sciences, International, North America, United States of America

Twitter

31 Jul 2021

@IAM_Alerts Dozens of tech businesses have promised to track patenting performance among women and other under-represented inve… https://t.co/QfoyynVQpn Read more

30 Jul 2021

@IAM_Alerts The only major innovators that sit outside Via's new pool seem to be Qualcomm and Technicolor… https://t.co/CUiy0mtnK1 Read more

30 Jul 2021

@IAM_Alerts This looks to be far more significant than the news out of South Africa earlier in the week … https://t.co/BOkuv5fdEk Read more

29 Jul 2021

@IAM_Alerts Nokia’s second quarter financials show its IP licensing business operating on margins that far exceed those of the… https://t.co/2z4VDmkUxz Read more

Find an expert

Michael Ritscher

Partner

Zurich, Switzerland

MLL Meyerlustenberger Lachenal Froriep Ltd

View full biography